How to buy Dicerna Pharmaceuticals stock (DRNA)

Dicerna Pharmaceuticals is a biotechnology business based in the US. Dicerna Pharmaceuticals shares (DRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $38.22 – the same closing value as a week prior. Dicerna Pharmaceuticals employs 302 staff and has a trailing 12-month revenue of around $192.9 million.

Our top picks for where to buy Dicerna Pharmaceuticals stock

Buy Dicerna Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Dicerna Pharmaceuticals stock price (NASDAQ: DRNA)

Use our graph to track the performance of DRNA stocks over time.

Dicerna Pharmaceuticals shares at a glance

• Key figures

Information last updated 2022-02-20.

Latest market close	$38.22
52-week range	$0.00 - $0.00
50-day moving average more info button	$31.45
200-day moving average more info button	$28.97
Wall St. target price	$38.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.63

Is it a good time to buy Dicerna Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dicerna Pharmaceuticals price performance over time

Historical closes compared with the close of $38.22 from 2021-12-29

1 week (2024-10-17)	N/A
1 month (2024-09-24)	N/A
3 months (2024-07-24)	N/A
6 months (2024-04-24)	N/A

1 year (2023-10-24)	N/A
2 years (2022-10-24)	N/A
3 years (2021-10-28)	78.18%
5 years (2019-10-28)	133.19%

Dicerna Pharmaceuticals financials

Revenue TTM	$192.9 million
Gross profit TTM	$-41,077,000
Return on assets TTM	-10.43%
Return on equity TTM	-95.22%
Profit margin	-64.53%
Book value	$1.38
Market Capitalization more info button	$3 billion

TTM: trailing 12 months

Dicerna Pharmaceuticals share dividends

We're not expecting Dicerna Pharmaceuticals to pay a dividend over the next 12 months.

Dicerna Pharmaceuticals share price volatility

Over the last 12 months, Dicerna Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dicerna Pharmaceuticals's is 0.786. This would suggest that Dicerna Pharmaceuticals's shares are less volatile than average (for this exchange).

Dicerna Pharmaceuticals overview

Dicerna Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.

Frequently asked questions

null
What percentage of Dicerna Pharmaceuticals is owned by insiders or institutions?
Currently 7.434% of Dicerna Pharmaceuticals shares are held by insiders and 88.539% by institutions. How many people work for Dicerna Pharmaceuticals?
Latest data suggests 302 work at Dicerna Pharmaceuticals. When does the fiscal year end for Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals's fiscal year ends in December. Where is Dicerna Pharmaceuticals based?
Dicerna Pharmaceuticals's address is: 75 Hayden Avenue, Lexington, MA, United States, 02421 What is Dicerna Pharmaceuticals's ISIN number?
Dicerna Pharmaceuticals's international securities identification number is: US2530311081 What is Dicerna Pharmaceuticals's CUSIP number?
Dicerna Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 253031108